The Third Party Peek.........
omolyanlid.......Transition was approached by other parties with richer offers but there was no game plan.......no roadmap or performance guarantees.......Dr. Cruz and the boys did their DD on all the Co.'s and Elan won out even though it wasn't the highest bidder! It was noted at the time by Dr. Cruz that Elan was coming off some hard times because of what you mention, but that after careful DD the Financial Stability of Elan was very Strong......but don't kid yourself, Dr. Cruz chose Elan for their Alzheimers Experience and Partnership Attitude and dedication and passion to finding the Alzheimers Answer.
The fact that the re-introduction of Natalizumab (Tysabri) knocked MS-IET off the Transition Pipeline is of no consideration in this case and it is noted in Q1/07 Financials as the factor in discontinuing it. Elan weathered the storm and hurdles and thats the risk factor with any Biotech or Big Pharma and it just comes down to your individual risk tolerance..........plain and simple.
GLA